{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T13:58:06Z","timestamp":1784901486782,"version":"3.55.0"},"reference-count":141,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,7]],"date-time":"2022-08-07T00:00:00Z","timestamp":1659830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,7]],"date-time":"2022-08-07T00:00:00Z","timestamp":1659830400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Hangzhou key project of medical health science and technology","award":["ZD20220022"],"award-info":[{"award-number":["ZD20220022"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Insulin and incretin-based drugs are important antidiabetic agents with complex effects on cell growth and metabolism. Emerging evidence shows that insulin and incretin-based drugs are associated with altered risk of biliary tract cancer (BTC). Observational study reveals that insulin is associated with an increased risk of extrahepatic cholangiocarcinoma (ECC), but not intrahepatic cholangiocarcinoma (ICC) or gallbladder cancer (GBC). This type-specific effect can be partly explained by the cell of origin and heterogeneous genome landscape of the three subtypes of BTC. Similar to insulin, incretin-based drugs also exhibit very interesting contradictions and inconsistencies in response to different cancer phenotypes, including BTC. Both epidemiological and experimental evidence suggests that incretin-based drugs can be a promoter of some cancers and an inhibitor of others. It is now more apparent that this type of drugs has a broader range of physiological effects on the body, including regulation of endoplasmic reticulum stress, autophagy, metabolic reprogramming, and gene expression. In particular, dipeptidyl peptidase-4 inhibitors (DPP-4i) have a more complex effect on cancer due to the multi-functional nature of DPP-4. DPP-4 exerts both catalytic and non-enzymatic functions to regulate metabolic homeostasis, immune reaction, cell migration, and proliferation. In this review, we collate the epidemiological and experimental evidence regarding the effect of these two classes of drugs on BTC to provide valuable information.<\/jats:p>","DOI":"10.1007\/s12672-022-00536-8","type":"journal-article","created":{"date-parts":[[2022,8,7]],"date-time":"2022-08-07T08:02:37Z","timestamp":1659859357000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["The role of insulin and incretin-based drugs in biliary tract cancer: epidemiological and experimental evidence"],"prefix":"10.1007","volume":"13","author":[{"given":"Hua","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,7]]},"reference":[{"issue":"5","key":"536_CR1","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.jhep.2018.01.009","volume":"68","author":"CP Wardell","year":"2018","unstructured":"Wardell CP, Fujita M, Yamada T. et.al. Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations. J Hepatol. 2018;68(5):959\u201369.","journal-title":"J Hepatol"},{"issue":"9","key":"536_CR2","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1158\/2159-8290.CD-17-0245","volume":"7","author":"JW Valle","year":"2017","unstructured":"Valle JW, Lamarca A, Goyal L. New horizons for precision medicine in biliary tract cancers. Cancer Discov. 2017;7(9):943\u201362.","journal-title":"Cancer Discov"},{"key":"536_CR3","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jhep.2019.09.007","volume":"72","author":"O Clements","year":"2020","unstructured":"Clements O, Eliahoo J, Kim JU. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a systematic review and meta-analysis. J Hepatol. 2020;72:95\u2013103.","journal-title":"J Hepatol"},{"key":"536_CR4","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.cgh.2017.08.017","volume":"16","author":"LA Torre","year":"2018","unstructured":"Torre LA, Siegel RL, Islami F. Worldwide burden of and trends in mortality from gallbladder and other biliary tract cancers. Clin Gastroenterol Hepatol. 2018;16:427\u201337.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"536_CR5","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1002\/hep.24351","volume":"54","author":"GL Tyson","year":"2011","unstructured":"Tyson GL, El-Serag HB. Risk factors for cholangiocarcinoma. Hepatology. 2011;54:173\u201384.","journal-title":"Hepatology"},{"key":"536_CR6","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1002\/ijc.22283","volume":"120","author":"TM Welzel","year":"2007","unstructured":"Welzel TM, Mellemkjaer L, Gloria G, et al. Risk factors for intrahepatic cholangiocarcinoma in a low-risk population: a nationwide case-control study. Int J Cancer. 2007;120:638\u201341.","journal-title":"Int J Cancer"},{"key":"536_CR7","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1053\/j.gastro.2004.12.048","volume":"128","author":"YH Shaib","year":"2005","unstructured":"Shaib YH, El-Serag HB, Davila JA. et.al. Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study. Gastroenterology. 2005;128:620\u20136.","journal-title":"Gastroenterology"},{"key":"536_CR8","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.diabres.2021.109119","volume":"183","author":"H Sun","year":"2022","unstructured":"Sun H, Saeedi P, Karuranga S, et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183:109\u201319.","journal-title":"Diabetes Res Clin Pract"},{"issue":"32","key":"536_CR9","doi-asserted-by":"publisher","first-page":"3647","DOI":"10.1200\/JCO.2017.73.4491","volume":"35","author":"JW Wu","year":"2017","unstructured":"Wu JW, Azoulay L, Majdan A. Long-term use of long-acting insulin analogs and breast cancer incidence in women with type 2 diabetes. J Clin Oncol. 2017;35(32):3647\u201353.","journal-title":"J Clin Oncol"},{"key":"536_CR10","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1053\/j.gastro.2009.04.013","volume":"137","author":"D Li","year":"2009","unstructured":"Li D, Yeung SC, Hassan MM. et.al. Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology. 2009;137:482\u20138.","journal-title":"Gastroenterology"},{"issue":"22","key":"536_CR11","doi-asserted-by":"publisher","first-page":"6354","DOI":"10.1158\/0008-5472.CAN-18-0687","volume":"78","author":"JW Russo","year":"2018","unstructured":"Russo JW, Gao C, Bhasin SS, et al. Downregulation of dipeptidyl peptidase 4 accelerates progression to castration-resistant prostate cancer. Cancer Res. 2018;78(22):6354\u201362.","journal-title":"Cancer Res"},{"issue":"17","key":"536_CR12","doi-asserted-by":"publisher","first-page":"248","DOI":"10.18632\/oncotarget.8399","volume":"7","author":"CH Tseng","year":"2016","unstructured":"Tseng CH. Sitagliptin use and thyroid cancer risk in patients with type 2 diabetes. Oncotarget. 2016;7(17):248: 71\u201379.","journal-title":"Oncotarget"},{"issue":"1","key":"536_CR13","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1111\/eci.12570","volume":"46","author":"CH Tseng","year":"2016","unstructured":"Tseng CH. Sitagliptin and pancreatic cancer risk in patients with type 2 diabetes. Eur J Clin Invest. 2016;46(1):70\u20139.","journal-title":"Eur J Clin Invest"},{"issue":"6","key":"536_CR14","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1055\/a-1345-7890","volume":"71","author":"A Shadboorestan","year":"2021","unstructured":"Shadboorestan A, Tarighi P, Koosha M, et al. Growth promotion and increased ATP-binding cassette transporters expression by liraglutide in triple negative breast cancer cell line MDA-MB-231. Drug Res (Stuttg). 2021;71(6):307\u201311.","journal-title":"Drug Res (Stuttg)"},{"key":"536_CR15","doi-asserted-by":"publisher","DOI":"10.1530\/EC-21-0546","author":"X Qi","year":"2022","unstructured":"Qi X, He P, Yao H, et al. Insulin therapy and biliary tract cancer: insights from real-world data. Endocr Connect. 2022. doi:https:\/\/doi.org\/10.1530\/EC-21-0546.","journal-title":"Endocr Connect"},{"issue":"5","key":"536_CR16","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1001\/jamainternmed.2022.0338","volume":"182","author":"L He","year":"2022","unstructured":"He L, Wang J, Ping F, et al. Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: a systematic review and meta-analysis of randomized clinical trials. JAMA Intern Med. 2022;182(5):513\u20139.","journal-title":"JAMA Intern Med"},{"key":"536_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k4880","author":"D Abrahami","year":"2018","unstructured":"Abrahami D, Douros A, Yin H, et al. Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study. BMJ. 2018. doi:https:\/\/doi.org\/10.1136\/bmj.k4880.","journal-title":"BMJ"},{"key":"536_CR18","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/s41574-020-0329-9","volume":"16","author":"BD Hopkins","year":"2020","unstructured":"Hopkins BD, Goncalves MD, Cantley LC. Insulin-PI3 K signalling: an evolutionarily insulated metabolic driver of cancer. Nat Rev Endocrinol. 2020;16:276\u201383.","journal-title":"Nat Rev Endocrinol"},{"key":"536_CR19","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/s41586-018-0343-4","volume":"560","author":"BD Hopkins","year":"2018","unstructured":"Hopkins BD, Pauli C, Du X, et al. Suppression of insulin feedback enhances the efficacy of PI3 K inhibitors. Nature. 2018;560:499\u2013503.","journal-title":"Nature"},{"key":"536_CR20","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1016\/j.cmet.2019.03.010","volume":"29","author":"A Molinaro","year":"2019","unstructured":"Molinaro A, Becattini B, Mazzoli A, et al. Insulin-driven PI3K-AKT signaling in the hepatocyte is mediated by redundant PI3K\u03b1 and PI3K\u03b2 activities and Is promoted by RAS. Cell Metab. 2019;29:1400\u20139.","journal-title":"Cell Metab"},{"key":"536_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/nu9111176","author":"MS Yoon","year":"2017","unstructured":"Yoon MS. The role of mammalian target of rapamycin (mTOR) in insulin signaling. Nutrients. 2017. doi:https:\/\/doi.org\/10.3390\/nu9111176.","journal-title":"Nutrients"},{"key":"536_CR22","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1042\/BST20130034","volume":"41","author":"I Nemazanyy","year":"2013","unstructured":"Nemazanyy I, Espeillac C, Pende M, Panasyuk G. Role of PI3 K, mTOR and Akt2 signalling in hepatic tumorigenesis via the control of PKM2 expression. Biochem Soc Trans. 2013;41:917\u201322.","journal-title":"Biochem Soc Trans"},{"key":"536_CR23","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.ceb.2005.09.009","volume":"17","author":"DD Sarbassov","year":"2005","unstructured":"Sarbassov DD, Ali SM, Sabatini DM. Growing roles for the mTOR pathway. Curr Opin Cell Biol. 2005;17:596\u2013603.","journal-title":"Curr Opin Cell Biol"},{"key":"536_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s12918-016-0281-4","author":"B Di Camillo","year":"2016","unstructured":"Di Camillo B, Carlon A, Eduati F, et al. A rule-based model of insulin signalling pathway. BMC Syst Biol. 2016. doi:https:\/\/doi.org\/10.1186\/s12918-016-0281-4.","journal-title":"BMC Syst Biol"},{"issue":"6","key":"536_CR25","doi-asserted-by":"publisher","first-page":"4634","DOI":"10.1016\/S0021-9258(17)41823-0","volume":"269","author":"K Yonezawa","year":"1994","unstructured":"Yonezawa K, Ando A, Kaburagi Y, et al. Signal transduction pathways from insulin receptors to Ras. Analysis by mutant insulin receptors. J Biol Chem. 1994;269(6):4634\u201340.","journal-title":"J Biol Chem"},{"key":"536_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/1478-811X-7-14","author":"K Mardilovich","year":"2009","unstructured":"Mardilovich K, Pankratz SL, Shaw LM. Expression and function of the insulin receptor substrate proteins in cancer. Cell Commun Signal. 2009. doi:https:\/\/doi.org\/10.1186\/1478-811X-7-14.","journal-title":"Cell Commun Signal"},{"key":"536_CR27","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1210\/er.2008-0047","volume":"30","author":"A Belfiore","year":"2009","unstructured":"Belfiore A, Frasca F, Pandini G, et al. Insulin receptor isoforms and insulin receptor\/insulin-like growth factor receptor hybrids in physiology and disease. Endocr Rev. 2009;30:586\u2013623.","journal-title":"Endocr Rev"},{"key":"536_CR28","first-page":"972","volume":"86","author":"Y Kido","year":"2001","unstructured":"Kido Y, Nakae J, Accili D. The insulin receptor and its cellular targets. J Clin Endocrinol Metab. 2001;86:972\u20139.","journal-title":"J Clin Endocrinol Metab"},{"key":"536_CR29","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.201907210","author":"T Gutmann","year":"2020","unstructured":"Gutmann T, Sch\u00e4fer IB, Poojari C, et al. Cryo-EM structure of the complete and ligand-saturated insulin receptor ectodomain. J Cell Biol. 2020. doi:https:\/\/doi.org\/10.1083\/jcb.201907210.","journal-title":"J Cell Biol"},{"key":"536_CR30","first-page":"3577","volume":"14","author":"MG Myers","year":"1994","unstructured":"Myers MG, Wang LM, Sun XJ, et al. Role of IRS-1-GRB-2 complexes in insulin signaling. Mol Cell Biol. 1994;14:3577\u201387.","journal-title":"Mol Cell Biol"},{"key":"536_CR31","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2019474118","author":"H Nagao","year":"2021","unstructured":"Nagao H, Cai W, Wewer Albrechtsen NJ, et al. Distinct signaling by insulin and IGF-1 receptors and their extra- and intracellular domains. Proc Natl Acad Sci USA. 2021. https:\/\/doi.org\/10.1073\/pnas.2019474118.","journal-title":"Proc Natl Acad Sci USA"},{"key":"536_CR32","doi-asserted-by":"publisher","DOI":"10.1172\/JCI16290","author":"S Zhang","year":"2003","unstructured":"Zhang S, Weinheimer C, Courtois M, et al. The role of the Grb2-p38 MAPK signaling pathway in cardiac hypertrophy and fibrosis. J Clin Invest. 2003. doi:https:\/\/doi.org\/10.1172\/JCI16290.","journal-title":"J Clin Invest"},{"key":"536_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cr.7290105","author":"W Zhang","year":"2002","unstructured":"Zhang W, Liu HT. MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Res. 2002. doi:https:\/\/doi.org\/10.1038\/sj.cr.7290105.","journal-title":"Cell Res"},{"key":"536_CR34","doi-asserted-by":"publisher","first-page":"3013","DOI":"10.1038\/sj.onc.1203621","volume":"19","author":"A Schnelzer","year":"2000","unstructured":"Schnelzer A, Prechtel D, Knaus U, et al. Rac1 in human breast cancer: overexpression, mutation analysis, and characterization of a new isoform, Rac1b. Oncogene. 2000;19:3013\u201320.","journal-title":"Oncogene"},{"key":"536_CR35","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1158\/1535-7163.MCT-13-0164","volume":"12","author":"HK Bid","year":"2013","unstructured":"Bid HK, Roberts RD, Manchanda PK, et al. RAC1: an emerging therapeutic option for targeting cancer angiogenesis and metastasis. Mol Cancer Ther. 2013;12:1925\u201334.","journal-title":"Mol Cancer Ther"},{"key":"536_CR36","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1111\/cge.12908","volume":"91","author":"T Zou","year":"2017","unstructured":"Zou T, Mao X, Yin J, et al. Emerging roles of RAC1 in treating lung cancer patients: emerging roles of RAC1 in treating lung cancer patients. Clin Genet. 2017;91:520\u20138.","journal-title":"Clin Genet"},{"key":"536_CR37","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/ncb2455","volume":"14","author":"WH Yang","year":"2012","unstructured":"Yang WH, Lan HY, Huang CH, et al. RAC1 activation mediates Twist1-induced cancer cell migration. Nat Cell Biol. 2012;14:366\u201374.","journal-title":"Nat Cell Biol"},{"key":"536_CR38","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1053\/j.gastro.2011.04.043","volume":"141","author":"I Heid","year":"2011","unstructured":"Heid I, Lubeseder\u2013Martellato C, Sipos B, et al. Early requirement of Rac1 in a mouse model of pancreatic cancer. Gastroenterology. 2011;141:719\u201330.","journal-title":"Gastroenterology"},{"key":"536_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-020-01719-5","author":"A Emami Nejad","year":"2021","unstructured":"Emami Nejad A, Najafgholian S, Rostami A, et al. The role of hypoxia in the tumor microenvironment and development of cancer stem cell: a novel approach to developing treatment. Cancer Cell Int. 2021. doi:https:\/\/doi.org\/10.1186\/s12935-020-01719-5.","journal-title":"Cancer Cell Int"},{"issue":"10","key":"536_CR40","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/nrd917","volume":"1","author":"P De Meyts","year":"2002","unstructured":"De Meyts P, Whittaker J. Structural biology of insulin and IGF1 receptors: implications for drug design. Nat Rev Drug Discov. 2002;1(10):769\u201383.","journal-title":"Nat Rev Drug Discov"},{"issue":"10","key":"536_CR41","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1002\/j.1460-2075.1986.tb04528.x","volume":"5","author":"A Ullrich","year":"1986","unstructured":"Ullrich A, Gray A, Tam AW, et al. Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity. EMBO J. 1986;5(10):2503\u201312.","journal-title":"EMBO J"},{"issue":"Suppl A","key":"536_CR42","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/S1096-6374(00)90005-4","volume":"10","author":"D Le Roith","year":"2000","unstructured":"Le Roith D. Regulation of proliferation and apoptosis by the insulin-like growth factor I receptor. Growth Horm IGF Res. 2000;10(Suppl A):12\u20133.","journal-title":"Growth Horm IGF Res"},{"issue":"6","key":"536_CR43","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1210\/edrv.22.6.0452","volume":"22","author":"J Nakae","year":"2001","unstructured":"Nakae J, Kido Y, Accili D. Distinct and overlapping functions of insulin and IGF-I receptors. Endocr Rev. 2001;22(6):818\u201335.","journal-title":"Endocr Rev"},{"issue":"22","key":"536_CR44","doi-asserted-by":"publisher","first-page":"17235","DOI":"10.1074\/jbc.M110.118620","volume":"285","author":"J Boucher","year":"2010","unstructured":"Boucher J, Tseng YH, Kahn CR. Insulin and insulin-like growth factor-1 receptors act as ligand-specific amplitude modulators of a common pathway regulating gene transcription. J Biol Chem. 2010;285(22):17235\u201345.","journal-title":"J Biol Chem"},{"issue":"3","key":"536_CR45","first-page":"872","volume":"79","author":"K Brismar","year":"1994","unstructured":"Brismar K, Fernqvist-Forbes E, Wahren J, Hall K. Effect of insulin on the hepatic production of insulin-like growth factor-binding protein-1 (IGFBP-1), IGFBP-3, and IGF-I in insulin-dependent diabetes. J Clin Endocrinol Metab. 1994;79(3):872\u20138.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"536_CR46","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrendo.2010.171","volume":"7","author":"PE Clayton","year":"2011","unstructured":"Clayton PE, Banerjee I, Murray PG, Renehan AG. Growth hormone, the insulin-like growth factor axis, insulin and cancer risk. Nat Rev Endocrinol. 2011;7(1):11\u201324.","journal-title":"Nat Rev Endocrinol"},{"issue":"4","key":"536_CR47","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1053\/j.gastro.2004.07.011","volume":"127","author":"YX Yang","year":"2004","unstructured":"Yang YX, Hennessy S, Lewis JD. Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients. Gastroenterology. 2004;127(4):1044\u201350.","journal-title":"Gastroenterology"},{"key":"536_CR48","doi-asserted-by":"publisher","DOI":"10.1186\/1746-1596-9-91","author":"S Yin","year":"2014","unstructured":"Yin S, Bai H, Jing D. Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients: a systemic review and meta-analysis. Diagn Pathol. 2014. doi:https:\/\/doi.org\/10.1186\/1746-1596-9-91.","journal-title":"Diagn Pathol"},{"key":"536_CR49","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00443","author":"CH Tseng","year":"2019","unstructured":"Tseng CH. Human insulin therapy is associated with an increased risk of lung cancer: a population-based retrospective cohort study. Front Endocrinol (Lausanne). 2019. https:\/\/doi.org\/10.3389\/fendo.2019.00443.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"536_CR50","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-015-1876-7","author":"CH Tseng","year":"2015","unstructured":"Tseng CH. Prolonged use of human insulin increases breast cancer risk in Taiwanese women with type 2 diabetes. BMC Cancer. 2015. doi:https:\/\/doi.org\/10.1186\/s12885-015-1876-7.","journal-title":"BMC Cancer"},{"issue":"4","key":"536_CR51","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1038\/ajg.2011.483","volume":"107","author":"M Bodmer","year":"2012","unstructured":"Bodmer M, Becker C, Meier C, et al. Use of antidiabetic agents and the risk of pancreatic cancer: a case-control analysis. Am J Gastroenterol. 2012;107(4):620\u20136.","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"536_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/MEG.0000000000001001","volume":"30","author":"XL Liu","year":"2018","unstructured":"Liu XL, Wu H, Zhao LG, et al. Association between insulin therapy and risk of liver cancer among diabetics: a meta-analysis of epidemiological studies. Eur J Gastroenterol Hepatol. 2018;30(1):1\u20138.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"536_CR53","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.2337\/dc08-2175","volume":"32","author":"G Libby","year":"2009","unstructured":"Libby G, Donnelly LA, Donnan PT, et al. New users of metformin are at low risk of incident cancer:a cohort study among people with type 2 diabetes. Diabetes Care. 2009;32:1620\u20135.","journal-title":"Diabetes Care"},{"key":"536_CR54","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/570356","author":"L Miele","year":"2015","unstructured":"Miele L, Bosetti C, Turati F, et al. Diabetes and insulin therapy, but not metformin, are related to hepatocellular cancer risk. Gastroenterol Res Pract. 2015. https:\/\/doi.org\/10.1155\/2015\/570356.","journal-title":"Gastroenterol Res Pract"},{"key":"536_CR55","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14112719","author":"M Vicentini","year":"2022","unstructured":"Vicentini M, Ballotari P, Venturelli F, et al. Impact of insulin therapies on cancer incidence in type 1 and type 2 diabetes: a population-based cohort study in Reggio Emilia, Italy. Cancers (Basel). 2022. https:\/\/doi.org\/10.3390\/cancers14112719.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"536_CR56","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s10120-021-01236-y","volume":"25","author":"M Saisana","year":"2022","unstructured":"Saisana M, Griffin SM, May FEB. Insulin and the insulin receptor collaborate to promote human gastric cancer. Gastric Cancer. 2022;25(1):107\u201323.","journal-title":"Gastric Cancer"},{"issue":"6","key":"536_CR57","doi-asserted-by":"publisher","first-page":"R225","DOI":"10.1530\/ERC-12-0203","volume":"19","author":"DP Rose","year":"2012","unstructured":"Rose DP, Vona-Davis L. The cellular and molecular mechanisms by which insulin influences breast cancer risk and progression. Endocr Relat Cancer. 2012;19(6):R225\u201341.","journal-title":"Endocr Relat Cancer"},{"key":"536_CR58","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrgastro.2016.51","volume":"13","author":"JM Banales","year":"2016","unstructured":"Banales JM, Cardinale V, Carpino G, et al. Expert consensus document: cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol. 2016;13:261\u201380.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"536_CR59","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","volume":"17","author":"JM Banales","year":"2020","unstructured":"Banales JM, Marin JJG, Lamarca A, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Reviews Gastroenterol Hepatol. 2020;17:557\u201388.","journal-title":"Nat Reviews Gastroenterol Hepatol"},{"issue":"9","key":"536_CR60","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1093\/annonc\/mdt204","volume":"24","author":"S Schlesinger","year":"2013","unstructured":"Schlesinger S, Aleksandrova K, Pischon T, et al. Diabetes mellitus, insulin treatment, diabetes duration, and risk of biliary tract cancer and hepatocellular carcinoma in a European cohort. Ann Oncol. 2013;24(9):2449\u201355.","journal-title":"Ann Oncol"},{"key":"536_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2021.100226","author":"A Moeini","year":"2021","unstructured":"Moeini A, Haber PK, Sia D. Cell of origin in biliary tract cancers and clinical implications. JHEP Rep. 2021. doi:https:\/\/doi.org\/10.1016\/j.jhepr.2021.100226.","journal-title":"JHEP Rep"},{"key":"536_CR62","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19061745","author":"H Nakagawa","year":"2018","unstructured":"Nakagawa H, Hayata Y, Yamada T, et al. Peribiliary glands as the cellular origin of biliary tract cancer. Int J Mol Sci. 2018. https:\/\/doi.org\/10.3390\/ijms19061745.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"536_CR63","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1002\/stem.2311","volume":"34","author":"G Carpino","year":"2016","unstructured":"Carpino G, Puca R, Cardinale V. Peribiliary glands as a niche of extrapancreatic precursors yielding insulin-producing cells in experimental and human diabetes. Stem Cells. 2016;34(5):1332\u201342.","journal-title":"Stem Cells"},{"key":"536_CR64","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.2823","author":"L Mu","year":"2017","unstructured":"Mu L, Zhu N, Zhang J, et al. Type 2 diabetes, insulin treatment and prognosis of breast cancer. Diabetes Metab Res Rev. 2017. doi:https:\/\/doi.org\/10.1002\/dmrr.2823.","journal-title":"Diabetes Metab Res Rev"},{"issue":"21","key":"536_CR65","doi-asserted-by":"publisher","first-page":"6033","DOI":"10.1158\/0008-5472.CAN-17-0687","volume":"77","author":"L Chen","year":"2017","unstructured":"Chen L, Chubak J, Boudreau DM, et al. Diabetes treatments and risks of adverse breast cancer outcomes among early-stage breast cancer patients: a SEER-medicare analysis. Cancer Res. 2017;77(21):6033\u201341.","journal-title":"Cancer Res"},{"issue":"4","key":"536_CR66","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1007\/s00125-011-2381-4","volume":"55","author":"B Carstensen","year":"2012","unstructured":"Carstensen B, Witte DR, Friis S. Cancer occurrence in Danish diabetic patients: duration and insulin effects. Diabetologia. 2012;55(4):948\u201358.","journal-title":"Diabetologia"},{"key":"536_CR67","doi-asserted-by":"publisher","first-page":"379","DOI":"10.2147\/CMAR.S157156","volume":"11","author":"M Ghidini","year":"2018","unstructured":"Ghidini M, Pizzo C, Botticelli A, et al. Biliary tract cancer: current challenges and future prospects. Cancer Manag Res. 2018;11:379\u201388.","journal-title":"Cancer Manag Res"},{"issue":"Suppl 1","key":"536_CR68","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/liv.14093","volume":"39","author":"T Kendall","year":"2019","unstructured":"Kendall T, Verheij J, Gaudio E. et.al. Anatomical, histomorphological and molecular classification of cholangiocarcinoma. Liver Int. 2019;39(Suppl 1):7\u201318.","journal-title":"Liver Int"},{"issue":"2","key":"536_CR69","first-page":"42","volume":"7","author":"I Roa","year":"2014","unstructured":"Roa I, de Toro G, Schalper K. Overexpression of the HER2\/neu gene: a new therapeutic possibility for patients With advanced gallbladder cancer. Gastrointest Cancer Res. 2014;7(2):42\u20138.","journal-title":"Gastrointest Cancer Res"},{"key":"536_CR70","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102070","author":"D Uprety","year":"2020","unstructured":"Uprety D, Adjei AA. KRAS: From undruggable to a druggable cancer target. Cancer Treat Rev. 2020. https:\/\/doi.org\/10.1016\/j.ctrv.2020.102070.","journal-title":"Cancer Treat Rev"},{"key":"536_CR71","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/cr.2008.328","volume":"19","author":"YE Zhang","year":"2009","unstructured":"Zhang YE. Non-Smad pathways in TGF-beta signaling. Cell Res. 2009;19:128\u201339.","journal-title":"Cell Res"},{"key":"536_CR72","doi-asserted-by":"publisher","first-page":"964","DOI":"10.7150\/ijbs.4564","volume":"8","author":"EC Connolly","year":"2012","unstructured":"Connolly EC, Freimuth J, Akhurst RJ. Complexities of TGF-beta targeted cancer therapy. Int J Biol Sci. 2012;8:964\u201378.","journal-title":"Int J Biol Sci"},{"issue":"4","key":"536_CR73","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1124\/pr.115.011395","volume":"68","author":"D Graaf Cd, Donnelly","year":"2016","unstructured":"Graaf Cd, Donnelly D, Wootten D, et al. Glucagon-like peptide-1 and its class B G protein-coupled receptors: a long march to therapeutic successes. Pharmacol Rev. 2016;68(4):954\u20131013.","journal-title":"Pharmacol Rev"},{"issue":"2","key":"536_CR74","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.regpep.2004.09.001","volume":"128","author":"PK Lund","year":"2005","unstructured":"Lund PK. The discovery of glucagon-like peptide 1. Regul Pept. 2005;128(2):93\u20136.","journal-title":"Regul Pept"},{"key":"536_CR75","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-02838-2","author":"R Carlessi","year":"2017","unstructured":"Carlessi R, Chen Y, Rowlands J, et al. GLP-1 receptor signalling promotes beta-cell glucose metabolism via mTOR-dependent HIF-1alpha activation. Sci Rep. 2017. doi:https:\/\/doi.org\/10.1038\/s41598-017-02838-2.","journal-title":"Sci Rep"},{"key":"536_CR76","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.peptides.2017.11.015","volume":"100","author":"J Rowlands","year":"2018","unstructured":"Rowlands J, Cruzat V, Carlessi R, et al. Insulin and IGF-1 receptor autocrine loops are not required for Exendin-4 induced changes to pancreatic \u03b2-cell bioenergetic parameters and metabolism in BRIN-BD11 cells. Peptides. 2018;100:140\u20139.","journal-title":"Peptides"},{"key":"536_CR77","doi-asserted-by":"publisher","first-page":"10538","DOI":"10.1074\/jbc.M109.091116","volume":"285","author":"M Cornu","year":"2010","unstructured":"Cornu M, Modi H, Kawamori D, et al. Glucagon-like peptide-1 increases beta-cell glucose competence and proliferation by translational induction of insulin-like growth factor-1 receptor expression. J Biol Chem. 2010;285:10538\u201345.","journal-title":"J Biol Chem"},{"key":"536_CR78","doi-asserted-by":"publisher","first-page":"16876","DOI":"10.1073\/pnas.1114228108","volume":"108","author":"S Van de","year":"2011","unstructured":"Van de S, Velde, Hogan MF, Montminy M. mTOR links incretin signaling to HIF induction in pancreatic beta cells. Proc Natl Acad Sci USA. 2011;108:16876\u201382.","journal-title":"Proc Natl Acad Sci USA"},{"key":"536_CR79","doi-asserted-by":"publisher","first-page":"4722","DOI":"10.1093\/emboj\/18.17.4722","volume":"1","author":"P Beguin","year":"1999","unstructured":"Beguin P, Nagashima K, Nishimura M, et al. PKA-mediated phosphorylation of the human K(ATP) channel: separate roles of Kir6.2 and SUR1 subunit phosphorylation. EMBO J. 1999;1:4722\u201332.","journal-title":"EMBO J"},{"key":"536_CR80","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/j.1463-1326.2012.01663.x","volume":"15","author":"AR Meloni","year":"2013","unstructured":"Meloni AR, DeYoung MB, Lowe C, et al. GLP-1 receptor activated insulin secretion from pancreatic \u03b2-cells: mechanism and glucose dependence. Diabetes Obes Metab. 2013;15:15\u201327.","journal-title":"Diabetes Obes Metab"},{"key":"536_CR81","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1113\/jphysiol.2007.143818","volume":"586","author":"GX Kang","year":"2008","unstructured":"Kang GX, Leech CA, Chepurny OG, et al. Role of the cAMP sensor Epac as a determinant of K-ATP channel ATP sensitivity in human pancreatic beta-cells and rat INS-1 cells. J Phys Lond. 2008;586:1307\u201319.","journal-title":"J Phys Lond"},{"key":"536_CR82","doi-asserted-by":"publisher","first-page":"6364","DOI":"10.1158\/1078-0432.CCR-07-4879","volume":"14","author":"MM Chitnis","year":"2008","unstructured":"Chitnis MM, Yuen JS, Protheroe AS, et al. The type 1 insulin-like growth factor receptor pathway. Clin Cancer Res. 2008;14:6364\u201370.","journal-title":"Clin Cancer Res"},{"key":"536_CR83","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/j.1476-5381.2011.01687.x","volume":"166","author":"D Donnelly","year":"2012","unstructured":"Donnelly D. The structure and function of the glucagon-like peptide-1 receptor and its ligands. Br J Pharmacol. 2012;166:27\u201341.","journal-title":"Br J Pharmacol"},{"key":"536_CR84","doi-asserted-by":"publisher","first-page":"124","DOI":"10.2337\/diabetes.52.1.124","volume":"52","author":"J Buteau","year":"2003","unstructured":"Buteau J, Foisy S, Joly E, et al. Glucagon-like peptide 1 induces pancreatic \u03b2-cell proliferation via transactivation of the epidermal growth factor receptor. Diabetes. 2003;52:124\u201332.","journal-title":"Diabetes"},{"key":"536_CR85","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1101\/gad.1097103","volume":"17","author":"US Jhala","year":"2003","unstructured":"Jhala US, Canettieri G, Screaton RA, et al. cAMP promotes pancreatic beta-cell survival via CREB-mediated induction of IRS2. Genes Dev. 2003;17:1575\u201380.","journal-title":"Genes Dev"},{"key":"536_CR86","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1007\/s00125-004-1379-6","volume":"47","author":"J Buteau","year":"2004","unstructured":"Buteau J, El-Assaad W, Rhodes C, et al. Glucagon-like peptide-1 prevents beta cell glucolipotoxicity. Diabetologia. 2004;47:806\u201315.","journal-title":"Diabetologia"},{"key":"536_CR87","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1677\/JOE-06-0148","volume":"193","author":"S Tsunekawa","year":"2007","unstructured":"Tsunekawa S, Yamamoto N, Tsukamoto K, et al. Protection of pancreatic \u03b2-cells by exendin-4 may involve the reduction of endoplasmic reticulum stress; in vivo and in vitro studies. J Endocrinol. 2007;193:65\u201374.","journal-title":"J Endocrinol"},{"key":"536_CR88","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1007\/s00125-011-2069-9","volume":"54","author":"M Shimoda","year":"2011","unstructured":"Shimoda M, Kanda Y, Hamamoto S, et al. The human glucagon-like peptide-1 analogue liraglutide preserves pancreatic beta cells via regulation of cell kinetics and suppression of oxidative and endoplasmic reticulum stress in a mouse model of diabetes. Diabetologia. 2011;54:1098\u2013108.","journal-title":"Diabetologia"},{"key":"536_CR89","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.cmet.2006.10.001","volume":"4","author":"B Yusta","year":"2006","unstructured":"Yusta B, Baggio LL, Estall JL, et al. GLP-1 receptor activation improves \u03b2 cell function and survival following induction of endoplasmic reticulum stress. Cell Metab. 2006;4:391\u2013406.","journal-title":"Cell Metab"},{"key":"536_CR90","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.tem.2014.02.003","volume":"25","author":"TJ Biden","year":"2014","unstructured":"Biden TJ, Boslem E, Chu KY, et al. Lipotoxic endoplasmic reticulum stress, \u03b2 cell failure, and type 2 diabetes mellitus. Trends Endocrinol Metab. 2014;25:389\u201398.","journal-title":"Trends Endocrinol Metab"},{"issue":"Suppl.","key":"536_CR91","doi-asserted-by":"publisher","first-page":"S73","DOI":"10.1016\/S1262-3636(08)73398-6","volume":"34","author":"J Buteau","year":"2008","unstructured":"Buteau J. GLP-1 receptor signaling: effects on pancreatic \u03b2-cell proliferation and survival. Diabetes Metab. 2008;34(Suppl.):2:S73\u20137.","journal-title":"Diabetes Metab"},{"key":"536_CR92","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.2337\/db09-0685","volume":"58","author":"DA Cunha","year":"2009","unstructured":"Cunha DA, Ladri\u00e8re L, Ortis F, et al. Glucagon-like peptide-1 agonists protect pancreatic \u03b2-cells from lipotoxic endoplasmic reticulum stress through upregulation of BiP and JunB. Diabetes. 2009;58:2851\u201362.","journal-title":"Diabetes"},{"key":"536_CR93","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.2337\/diab.44.9.1126","volume":"44","author":"CF Deacon","year":"1995","unstructured":"Deacon CF, Nauck MA, Toft-Nielsen M, et al. Both subcutaneously and intravenously administered glucagon-like peptide 1 are rapidly degraded from the NH2-terminus in type 2-diabetic patients and in healthy subjects. Diabetes. 1995;44:1126\u201331.","journal-title":"Diabetes"},{"key":"536_CR94","first-page":"E 458","volume":"271","author":"CF Deacon","year":"1996","unstructured":"Deacon CF, Pridal L, Klarskov L, et al. Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig. Am J Physiol. 1996;271:E 458\u2013E 464.","journal-title":"Am J Physiol"},{"key":"536_CR95","doi-asserted-by":"publisher","first-page":"401","DOI":"10.2147\/TCRM.S7313","volume":"6","author":"J Pinkney","year":"2010","unstructured":"Pinkney J, Fox T, Ranganath L. Selecting. GLP-1 agonists in the management of type 2 diabetes: differential pharmacology and therapeutic benefits of liraglutide and exenatide. Ther Clin Risk Manag. 2010;6:401\u201311.","journal-title":"Ther Clin Risk Manag"},{"key":"536_CR96","doi-asserted-by":"publisher","first-page":"3703","DOI":"10.1210\/jc.2007-2109","volume":"93","author":"CW Chia","year":"2008","unstructured":"Chia CW, Egan JM. Incretin-based therapies in type 2 diabetes mellitus. J Clin Endocrinol Metab. 2008;93:3703\u201316.","journal-title":"J Clin Endocrinol Metab"},{"key":"536_CR97","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2020.101102","author":"MA Nauck","year":"2021","unstructured":"Nauck MA, Quast DR, Wefers J, et al. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Mol Metab. 2021. doi:https:\/\/doi.org\/10.1016\/j.molmet.2020.101102.","journal-title":"Mol Metab"},{"key":"536_CR98","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-09898-4","author":"J Fusco","year":"2017","unstructured":"Fusco J, Xiao X, Prasadan K, et al. GLP-1\/Exendin-4 induces \u03b2-cell proliferation via the epidermal growth factor receptor. Sci Rep. 2017. https:\/\/doi.org\/10.1038\/s41598-017-09898-4.","journal-title":"Sci Rep"},{"issue":"6","key":"536_CR99","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","volume":"132","author":"LL Baggio","year":"2007","unstructured":"Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132(6):2131\u201357.","journal-title":"Gastroenterology"},{"issue":"2","key":"536_CR100","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.diabet.2008.09.007","volume":"35","author":"M Karaca","year":"2009","unstructured":"Karaca M, Magnan C, Kargar C. Functional pancreatic beta-cell mass: involvement in type 2 diabetes and therapeutic intervention. Diabetes Metab. 2009;35(2):77\u201384.","journal-title":"Diabetes Metab"},{"key":"536_CR101","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27103055","author":"R Yin","year":"2022","unstructured":"Yin R, Xu Y, Wang X, et al. Role of Dipeptidyl Peptidase 4 Inhibitors in Antidiabetic Treatment. Molecules. 2022. doi:https:\/\/doi.org\/10.3390\/molecules27103055.","journal-title":"Molecules"},{"issue":"3","key":"536_CR102","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.3892\/or.2015.4476","volume":"35","author":"Y Zhang","year":"2016","unstructured":"Zhang Y, Xu F, Liang H, et al. Exenatide inhibits the growth of endometrial cancer Ishikawa xenografts in nude mice. Oncol Rep. 2016;35(3):1340\u20138.","journal-title":"Oncol Rep"},{"issue":"2","key":"536_CR103","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s10549-011-1585-0","volume":"132","author":"H Ligumsky","year":"2012","unstructured":"Ligumsky H, Wolf I, Israeli S, et al. The peptide-hormone glucagon-like peptide-1 activates cAMP and inhibits growth of breast cancer cells. Breast Cancer Res Treat. 2012;132(2):449\u201361.","journal-title":"Breast Cancer Res Treat"},{"issue":"9","key":"536_CR104","doi-asserted-by":"publisher","first-page":"3362","DOI":"10.1210\/en.2011-1201","volume":"152","author":"JA Koehler","year":"2011","unstructured":"Koehler JA, Kain T, Drucker DJ. Glucagon-like peptide-1 receptor activation inhibits growth and augments apoptosis in murine CT26 colon cancer cells. Endocrinology. 2011;152(9):3362\u201372.","journal-title":"Endocrinology"},{"issue":"11","key":"536_CR105","doi-asserted-by":"publisher","first-page":"3891","DOI":"10.2337\/db13-1169","volume":"63","author":"T Nomiyama","year":"2014","unstructured":"Nomiyama T, Kawanami T, Irie S, et al. Exendin-4, a GLP-1 receptor agonist, attenuates prostate cancer growth. Diabetes. 2014;63(11):3891\u2013905.","journal-title":"Diabetes"},{"issue":"7","key":"536_CR106","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1001\/jamainternmed.2013.2720","volume":"173","author":"S Singh","year":"2013","unstructured":"Singh S, Chang H, Richards TM, et al. Glucagonlike peptide 1\u2013based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. JAMA Intern Med. 2013;173(7):534\u20139.","journal-title":"JAMA Intern Med"},{"issue":"3","key":"536_CR107","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.ejim.2013.01.009","volume":"24","author":"K Labuzek","year":"2013","unstructured":"Labuzek K, Koz\u0142owski M, Szkud\u0142apski D, et al. Incretin-based therapies in the treatment of type 2 diabetes\u2013more than meets the eye? Eur J Intern Med. 2013;24(3):207\u201312.","journal-title":"Eur J Intern Med"},{"key":"536_CR108","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1126\/science.8101391","volume":"261","author":"J Kameoka","year":"1993","unstructured":"Kameoka J, Tanaka T, Nojima Y, et al. Direct association of adenosine deaminase with a T cell activation antigen, CD26. Science. 1993;261:466\u20139.","journal-title":"Science"},{"key":"536_CR109","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.it.2008.02.010","volume":"29","author":"K Ohnuma","year":"2008","unstructured":"Ohnuma K, Dang NH, Morimoto C. Revisiting an old acquaintance: CD26 and its molecular mechanisms in T cell function. Trends Immunol. 2008;29:295\u2013301.","journal-title":"Trends Immunol"},{"key":"536_CR110","doi-asserted-by":"publisher","DOI":"10.1126\/science.aal3321","author":"PJ Thul","year":"2017","unstructured":"Thul PJ, \u00c5kesson L, Wiking M, et al. A subcellular map of the human proteome. Science. 2017. doi:https:\/\/doi.org\/10.1126\/science.aal3321.","journal-title":"Science"},{"key":"536_CR111","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00387","author":"Y Waumans","year":"2015","unstructured":"Waumans Y, Baerts L, Kehoe K, et al. The dipeptidyl peptidase family, prolyl oligopeptidase, and prolyl carboxypeptidase in the immune system and inflammatory disease, including atherosclerosis. Front Immunol. 2015. doi:https:\/\/doi.org\/10.3389\/fimmu.2015.00387.","journal-title":"Front Immunol"},{"key":"536_CR112","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00080","author":"CF Deacon","year":"2019","unstructured":"Deacon CF. Physiology and pharmacology of DPP-4 in glucose homeostasis and the treatment of type 2 diabetes. Front Endocrinol (Lausanne). 2019. https:\/\/doi.org\/10.3389\/fendo.2019.00080.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"536_CR113","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1038\/nm.2991","volume":"18","author":"HE Broxmeyer","year":"2012","unstructured":"Broxmeyer HE, Hoggatt J, O\u2019Leary HA, et al. Dipeptidylpeptidase 4 negatively regulates colony-stimulating factor activity and stress hematopoiesis. Nat Med. 2012;18:1786\u201396.","journal-title":"Nat Med"},{"key":"536_CR114","doi-asserted-by":"publisher","first-page":"3988","DOI":"10.1074\/jbc.274.7.3988","volume":"274","author":"P Proost","year":"1999","unstructured":"Proost P, Struyf S, Schols D, et al. Truncation of macrophage-derived chemokine by CD26\/ dipeptidyl-peptidase IV beyond its predicted cleavage site affects chemotactic activity and CC chemokine receptor 4 interaction. J Biol Chem. 1999;274:3988\u201393.","journal-title":"J Biol Chem"},{"key":"536_CR115","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107503","author":"S Shao","year":"2020","unstructured":"Shao S, Xu Q, Yu X, et al. Dipeptidyl peptidase 4 inhibitors and their potential immune modulatory functions. Pharmacol Ther. 2020. doi:https:\/\/doi.org\/10.1016\/j.pharmthera.2020.107503.","journal-title":"Pharmacol Ther"},{"key":"536_CR116","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.canlet.2018.01.064","volume":"420","author":"CJ Qin","year":"2018","unstructured":"Qin CJ, Zhao LH, Zhou X, et al. Inhibition of dipeptidyl peptidase IV prevents high fat diet-induced liver cancer angiogenesis by downregulating chemokine ligand 2. Cancer Lett. 2018;420:26\u201337.","journal-title":"Cancer Lett"},{"key":"536_CR117","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41590-019-0321-5","volume":"20","author":"C Hollande","year":"2019","unstructured":"Hollande C, Boussier J, Ziai J, et al. Inhibition of the dipeptidyl peptidase DPP4 (CD26) reveals IL-33-dependent eosinophil-mediated control of tumor growth. Nat Immunol. 2019;20:257\u201364.","journal-title":"Nat Immunol"},{"key":"536_CR118","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0098582","author":"CS Lam","year":"2014","unstructured":"Lam CS, Cheung AH, Wong SK, et al. Prognostic significance of CD26 in patients with colorectal cancer. PLoS ONE. 2014. doi:https:\/\/doi.org\/10.1371\/journal.pone.0098582.","journal-title":"PLoS ONE"},{"issue":"2","key":"536_CR119","doi-asserted-by":"publisher","first-page":"2995","DOI":"10.18632\/oncotarget.13820","volume":"8","author":"PI Liang","year":"2017","unstructured":"Liang PI, Yeh BW, Li WM, et al. DPP4\/CD26 overexpression in urothelial carcinoma confers an independent prognostic impact and correlates with intrinsic biological aggressiveness. Oncotarget. 2017;8(2):2995\u20133008.","journal-title":"Oncotarget"},{"issue":"21","key":"536_CR120","doi-asserted-by":"publisher","first-page":"5096","DOI":"10.1111\/bph.13274","volume":"172","author":"HJ Choi","year":"2015","unstructured":"Choi HJ, Kim JY, Lim SC, et al. Dipeptidyl peptidase 4 promotes epithelial cell transformation and breast tumourigenesis via induction of PIN1 gene expression. Br J Pharmacol. 2015;172(21):5096\u2013109.","journal-title":"Br J Pharmacol"},{"key":"536_CR121","doi-asserted-by":"publisher","first-page":"8679","DOI":"10.18632\/oncotarget.14412","volume":"8","author":"X Yang","year":"2017","unstructured":"Yang X, Zhang X, Wu R, et al. DPPIV promotes endometrial carcinoma cell proliferation, invasion and tumorigenesis. Oncotarget. 2017;8:8679\u201392.","journal-title":"Oncotarget"},{"key":"536_CR122","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/S0167-0115(99)00089-0","volume":"85","author":"R Mentlein","year":"1999","unstructured":"Mentlein R. Dipeptidyl-peptidase IV (CD26)\u2013role in the inactivation of regulatory peptides. Regul Pept. 1999;85:19\u201324.","journal-title":"Regul Pept"},{"key":"536_CR123","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1111\/j.1742-4658.2009.07526.x","volume":"277","author":"DM Yu","year":"2010","unstructured":"Yu DM, Yao TW, Chowdhury S, et al. The dipeptidyl peptidase IV family in cancer and cell biology. FEBS J. 2010;277:1126\u201344.","journal-title":"FEBS J"},{"key":"536_CR124","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1080\/713609354","volume":"40","author":"AM Lambeir","year":"2003","unstructured":"Lambeir AM, Durinx C, Scharp\u00e9 S, et al. Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci. 2003;40:209\u201394.","journal-title":"Crit Rev Clin Lab Sci"},{"key":"536_CR125","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2022.120370","author":"ZZ Liu","year":"2022","unstructured":"Liu ZZ, Duan XX, Yuan MC, et al. Glucagon-like peptide-1 receptor activation by liraglutide promotes breast cancer through NOX4\/ROS\/VEGF pathway. Life Sci. 2022. doi:https:\/\/doi.org\/10.1016\/j.lfs.2022.120370.","journal-title":"Life Sci"},{"issue":"1","key":"536_CR126","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1080\/07435800.2021.1955255","volume":"47","author":"J Wang","year":"2022","unstructured":"Wang J, Kim CH. Differential risk of cancer associated with glucagon-like peptide-1 receptor agonists: analysis of real-world databases. Endocr Res. 2022;47(1):18\u201325.","journal-title":"Endocr Res"},{"key":"536_CR127","doi-asserted-by":"publisher","DOI":"10.1177\/1559325821995651","author":"AA Alanteet","year":"2021","unstructured":"Alanteet AA, Attia HA, Shaheen S, et al. Anti-proliferative activity of glucagon-like peptide-1 receptor agonist on obesity-associated breast cancer: the impact on modulating adipokines\u2019 expression in adipocytes and cancer cells. Dose Response. 2021. https:\/\/doi.org\/10.1177\/1559325821995651.","journal-title":"Dose Response"},{"issue":"1","key":"536_CR128","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1053\/j.gastro.2007.04.007","volume":"133","author":"M Marzioni","year":"2007","unstructured":"Marzioni M, Alpini G, Saccomanno S, et al. Glucagon-like peptide-1 and its receptor agonist exendin-4 modulate cholangiocyte adaptive response to cholestasis. Gastroenterology. 2007;133(1):244\u201355.","journal-title":"Gastroenterology"},{"issue":"7","key":"536_CR129","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1136\/gut.2008.150870","volume":"58","author":"M Marzioni","year":"2009","unstructured":"Marzioni M, Alpini G, Saccomanno S, et al. Exendin-4, a glucagon-like peptide 1 receptor agonist, protects cholangiocytes from apoptosis. Gut. 2009;58(7):990\u20137.","journal-title":"Gut"},{"key":"536_CR130","doi-asserted-by":"publisher","first-page":"4313","DOI":"10.1007\/s11033-014-3302-7","volume":"41","author":"BD Chen","year":"2014","unstructured":"Chen BD, Zhao WC, Dong JD, et al. Expression of GLP-1R protein and its clinical role in intrahepatic cholangiocarcinoma tissues. Mol Biol Rep. 2014;41:4313\u201320.","journal-title":"Mol Biol Rep"},{"issue":"4","key":"536_CR131","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311\u201322.","journal-title":"N Engl J Med"},{"issue":"2","key":"536_CR132","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1111\/dom.12582","volume":"18","author":"LA Leiter","year":"2016","unstructured":"Leiter LA, Teoh H, Mosenzon O, et al. Frequency of cancer events with saxagliptin in the SAVOR-TIMI 53 trial. Diabetes Obes Metab. 2016;18(2):186\u201390.","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"536_CR133","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s00592-019-01444-0","volume":"57","author":"CB Giorda","year":"2020","unstructured":"Giorda CB, Picariello R, Tartaglino B, et al. Incretin-based therapy and risk of cholangiocarcinoma: a nested case-control study in a population of subjects with type 2 diabetes. Acta Diabetol. 2020;57(4):401\u20138.","journal-title":"Acta Diabetol"},{"issue":"10","key":"536_CR134","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1007\/s00125-021-05508-1","volume":"64","author":"P Ueda","year":"2021","unstructured":"Ueda P, Wintzell V, Melbye M, et al. Use of incretin-based drugs and risk of cholangiocarcinoma: Scandinavian cohort study. Diabetologia. 2021;64(10):2204\u201314.","journal-title":"Diabetologia"},{"issue":"1\u20133","key":"536_CR135","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.regpep.2012.08.005","volume":"179","author":"J Keller","year":"2012","unstructured":"Keller J, Trautmann ME, Haber H, et al. Effect of exenatide on cholecystokinin-induced gallbladder emptying in fasting healthy subjects. Regul Pept. 2012;179(1\u20133):77\u201383.","journal-title":"Regul Pept"},{"issue":"1","key":"536_CR136","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1411892","volume":"373","author":"X Pi-Sunyer","year":"2015","unstructured":"Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0\u00a0mg of liraglutide in weight management. N Engl J Med. 2015;373(1):11\u201322.","journal-title":"N Engl J Med"},{"issue":"5","key":"536_CR137","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s40520-015-0335-2","volume":"27","author":"H Korkmaz","year":"2015","unstructured":"Korkmaz H, Araz M, Alkan S, et al. Liraglutide-related cholelithiasis. Aging Clin Exp Res. 2015;27(5):751\u20133.","journal-title":"Aging Clin Exp Res"},{"issue":"10","key":"536_CR138","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1023\/A:1026678925120","volume":"43","author":"T Tolessa","year":"1998","unstructured":"Tolessa T, Gutniak M, Holst JJ, et al. Glucagon-like peptide-1 retards gastric emptying and small bowel transit in the rat: effect mediated through central or enteric nervous mechanisms. Dig Dis Sci. 1998;43(10):2284\u201390.","journal-title":"Dig Dis Sci."},{"issue":"12","key":"536_CR139","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1080\/00365521.2018.1530297","volume":"53","author":"JF Rehfeld","year":"2018","unstructured":"Rehfeld JF, Knop FK, Asmar A, et al. Cholecystokinin secretion is suppressed by glucagon-like peptide-1: clue to the mechanism of the adverse gallbladder events of GLP-1-derived drugs. Scand J Gastroenterol. 2018;53(12):1429\u201332.","journal-title":"Scand J Gastroenterol"},{"issue":"12","key":"536_CR140","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1111\/dom.12748","volume":"18","author":"MM Smits","year":"2016","unstructured":"Smits MM, Tonneijck L, Muskiet MH, et al. Biliary effects of liraglutide and sitagliptin, a 12-week randomized placebo-controlled trial in type 2 diabetes patients. Diabetes Obes Metab. 2016;18(12):1217\u201325.","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"536_CR141","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1001\/jamainternmed.2016.1531","volume":"176","author":"JL Faillie","year":"2016","unstructured":"Faillie JL, Yu OH, Yin H, et al. Association of bile duct and gallbladder diseases with the use of incretin-based drugs in patients with type 2 diabetes mellitus. JAMA Intern Med. 2016;176(10):1474\u201381.","journal-title":"JAMA Intern Med"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-022-00536-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-022-00536-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-022-00536-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,7]],"date-time":"2022-08-07T09:07:12Z","timestamp":1659863232000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-022-00536-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,7]]},"references-count":141,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["536"],"URL":"https:\/\/doi.org\/10.1007\/s12672-022-00536-8","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,7]]},"assertion":[{"value":"18 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"70"}}